雅各臣科研製藥(02633.HK):就於大中華區及亞太地區經選定市場分銷專科藥、品牌醫療保健產品及醫療器械成立合資公司
格隆匯6月15日丨雅各臣科研製藥(02633.HK)與健倍苗苗(02161.HK)聯合宣佈,於2022年6月15日,(i)萬隆的全資附屬公司華程國際發展有限公司("萬隆實體")(其控股股東為雲南白藥集團股份有限公司("雲南白藥",一間於深圳證券交易所上市的公司,證券代碼:000538));(ii)雅各臣的全資附屬公司Ferguson Healthcare Holdings (BVI) Limited("雅各臣實體");(iii)健倍苗苗的全資附屬公司Joy Wish Limited("健倍苗苗實體",連同萬隆實體及雅各臣實體統稱"合資夥伴");及(iv)萬隆雅健藥業有限公司("合資公司")訂立一份股東協議,據此,合資夥伴同意成立合資公司,主要從事(i)獲取專科藥(包括罕見病用藥)、非處方藥、品牌醫療保健品(包括草藥產品)及醫療器械("該等產品")的授權;(ii)於大中華區及亞太地區的經選定市場銷售及分銷該等產品;及(iii)發掘併購機會。
合資公司的目標為於大中華區及亞太地區之經選定市場的專科藥及品牌醫療保健品領域建立穩固基礎。萬隆集團、雅各臣集團及健倍苗苗集團均處於有利地位,可利用彼等各自的行業專業知識、市場能力、融資資源及區域網絡,為合資公司實現實質商機。
根據股東協議,合資公司將由萬隆實體、雅各臣實體及健倍苗苗實體分別擁有60%、20%及20%權益。合資夥伴對合資公司的投資承擔總額為600萬港元,有關金額將由合資夥伴於股東協議日期起計2年內按彼等各自於合資公司的持股比例出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.